Protective effect of sevoflurane pretreatment on liver ischemic-reperfusion injury in diabetes mellitus mice

doi:10.3877/cma.j.issn.2095-3232.2017.06.020

Abstract

Abstract:

Objective

To investigate the effect and mechanism of sevoflurane pretreatment on the liver ischemia-reperfusion injury (IRI) in diabetes mellitus mice model.

Methods

Twenty-four male db/db mice with type 2 diabetes mellitus, weighed 25-30 g each, were divided into the sham surgery group (Sham group), liver IRI group (IRI group), sevoflurane pretreatment group (S group) and sevoflurane pretreatment combined with ischemic-reperfusion group (SIR group), with 6 mice in each group. In Sham group, only the porta hepatis was exposed without blood occlusion. In IRI group, the hepatic portal occlusion was performed for 30 min and restored afterward. In S group, sham operation was conducted 120 min after inhalation of 2.4% sevoflurane. In SIR group, inhalation of 2.4% sevoflurane for 120 min was delivered before hepatic portal occlusion. The levels of serum ALT, AST, superoxide dismutase (SOD) and malondialdehyde (MDA) in liver tissue of each group were measured. The expression levels of nuclear factor-κB (NF-κB) and intercellular adhesion molecule-1 (ICAM-1) proteins in liver tissue were detected by Western blot. The tested results were compared using One-way ANOVA and LSD-t test.

Results

In SIR group, the level of serum ALT and AST was respectively (67±12) and (92±8) U/L, significantly lower than (88±12) and (117±15) U/L in IRI group (LSD-t=-4.18, -4.61; P<0.05). In SIR group, the SOD activity was (126±12) U/mg, significantly higher than (85±9) U/mg in IRI group (LSD-t=6.53, P<0.05). In SIR group, the MDA activity was (4.3±0.7) nmol/mg, significantly lower than (6.7±1.1) nmol/mg in IRI group (LSD-t=-5.85, P<0.05). In SIR group, the relative expression level of NF-κB and ICAM-1 protein was respectively 0.53±0.19 and 0.96±0.13, significantly lower than 0.97±0.13 and 1.29±0.11 in IRI group (LSD-t=-6.01, -5.63; P<0.05).

Conclusions

Sevoflurane pretreatment can mitigate IRI in diabetes mellitus mice, probably through enhancing the eliminating ability of free radicals, inhibiting NF-κB signaling pathway and down-regulating the expression of ICAM-1 in liver endothelial cells.

Key words: Reperfusion injury, NF-kappa B, Cell adhesion molecules, Superoxide dismutase, Sevoflurane

Shanshan Ou, Yuxiang Han, Xiaoyu Xiao, Lukun Yang, Yingxian Zhu. Protective effect of sevoflurane pretreatment on liver ischemic-reperfusion injury in diabetes mellitus mice[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(06): 509-512.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2017.06.020

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2017/V06/I06/509

Figures/Tables 3

References 20

[1]	Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9):948-959.
[2]	Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management[J]. J Hepatol, 2010, 53(1):199-206.
[3]	Parekh J, Corley DA, Feng S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation[J]. Am J Transplant, 2012, 12(8):2181-2187.
[4]	Zhao J, Wang F, Zhang Y, et al. Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition[J]. Circulation, 2013, 128(11 Suppl 1):S121-129.
[5]	Lurati Buse GA, Schumacher P, Seeberger E, et al. Randomized comparison of sevoflurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery[J]. Circulation, 2012, 126(23):2696-2704.
[6]	Zhou SP, Jiang P, Liu L, et al. Protective effect of sevoflurane on hepatic ischaemia/reperfusion injury in the rat: a dose-response study[J]. Eur J Anaesthesiol, 2013, 30(10):612-617.
[7]	周少朋，张雪霞，候冰宗，等．七氟醚预处理对大鼠肝脏缺血再灌注损伤的影响[J/CD]．消化肿瘤杂志(电子版)，2011，3(1):45-48.
[8]	张南文，吴伟芳，林剑鸣．不同浓度水合氯醛在两种雄性小鼠麻醉中的应用[J]．临床麻醉学杂志，2014，30(2):171-173.
[9]	Yamada F, Saito T, Abe T, et al. Ischemic preconditioning enhances regenerative capacity of hepatocytes in long-term ischemically damaged rat livers[J]. J Gastroenterol Hepatol, 2007, 22(11):1971-1977.
[10]	Gujral JS, Bucci TJ, Farhood A, et al. Mechanism of cell death during warm hepatic ischemia-reperfusion in rats: apoptosis or necrosis?[J]. Hepatology, 2001, 33(2):397-405.
[11]	Penna C, Mancardi D, Rastaldo R, et al. Cardioprotection: a radical view free radicals in pre and postconditioning[J]. Biochim Biophys Acta, 2009, 1787(7):781-793.
[12]	Karatzas T, Neri AA, Baibaki ME, et al. Rodent models of hepatic ischemia-reperfusion injury: time and percentage-related pathophysiological mechanisms[J]. J Surg Res, 2014, 191(2):399-412.
[13]	谢汉镔，葛缅，池信锦，等．肝移植围手术期缺血-再灌注胃氧化损伤发生机制[J/CD]．中华肝脏外科手术学电子杂志，2015，4(4):254-258.
[14]	Romanque UP, Uribe MM, Videla LA. Molecular mechanisms in liver ischemic-reperfusion injury and ischemic preconditioning[J]. Rev Med Chil, 2005, 133(4):469-476.
[15]	Luedde T, Liedtke C, Manns MP, et al. Losing balance: cytokine signaling and cell death in the context of hepatocyte injury and hepatic failure[J]. Eur Cytokine Netw, 2002, 13(4):377-383.
[16]	Cutrin JC, Boveris A, Zingaro B, et al. In situ determination by surface chemiluminescence of temporal relationships between evolving warm ischemia-reperfusion injury in rat liver and phagocyte activation and recruitment[J]. Hepatology, 2000, 31(3):622-632.
[17]	Hisama N, Yamaguchi Y, Ishiko T, et al. Kupffer cell production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion injury in rats[J]. Hepatology, 1996, 24(5):1193-1198.
[18]	El-Wahsh M, Seifalian AM, Fuller BJ, et al. Induction of adhesion molecule expression in liver ischaemia-reperfusion injury is associated with impaired hepatic parenchymal microcirculation[J]. Br J Surg, 2004, 91(8):1034-1039.
[19]	Zheng J, Wang WL. Risk factors of metabolic syndrome after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(6):582-587.
[20]	Meng GX, Yuan Q, Wei LP, et al. Protein kinase C-beta inhibitor treatment attenuates hepatic ischemia and reperfusion injury in diabetic rats[J]. Exp Ther Med, 2016, 11(2):565-570.

组别	鼠数（只）	ALT	AST
Sham组	6	21±30^aa	38±4^aa
IRI组	6	88±12^a^a	117±15^a^a
S组	6	23±40^aa	43±4^aa
SIR组	6	67±12^ab	92±8^ab
F值	?	87.73	102.84
P值	?	<0.05	<0.05

组别	鼠数（只）	ALT	AST
Sham组	6	21±30^aa	38±4^aa
IRI组	6	88±12^a^a	117±15^a^a
S组	6	23±40^aa	43±4^aa
SIR组	6	67±12^ab	92±8^ab
F值	?	87.73	102.84
P值	?	<0.05	<0.05

组别	鼠数（只）	SOD（U/mg）	MDA（nmol/mg）
Sham组	6	157±13^ab	2.6±0.4^ab
IRI组	6	85±9^ab	6.7±1.1^ab
S组	6	148±10^ab	2.6±0.3^ab
SIR组	6	126±12^ab	4.3±0.7^ab
F值	?	50.95	46.45
P值	?	<0.05	<0.05

组别	鼠数（只）	SOD（U/mg）	MDA（nmol/mg）
Sham组	6	157±13^ab	2.6±0.4^ab
IRI组	6	85±9^ab	6.7±1.1^ab
S组	6	148±10^ab	2.6±0.3^ab
SIR组	6	126±12^ab	4.3±0.7^ab
F值	?	50.95	46.45
P值	?	<0.05	<0.05

组别	鼠数（只）	NF-κB	ICAM-1
Sham组	6	0.30±0.04^ab	0.75±0.09^ab
IRI组	6	0.97±0.13^ab	1.29±0.11^ab
S组	6	0.32±0.11^ab	0.74±0.08^ab
SIR组	6	0.53±0.19^ab	0.96±0.13^ab
F值	?	36.71	39.44
P值	?	<0.05	<0.05

Please choose a citation manager

Content to export